Posaconazole or isavuconazole as sole or predominant antifungal therapy for COVID-19-associated mucormycosis. A retrospective observational case series
The surge of COVID-19 associated Mucormycosis (CAM) in India during the second wave of COVID-19 led to lack of availability of amphotericin B(AmB). We retrospectively evaluated the outcome in 28 consecutive patients with CAM who received posaconazole (PCZ) or isavuconazole (ISVCZ) as sole or predomi...
Main Authors: | Rajeev Soman, Sourabh Chakraborty, Geethu Joe |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-07-01
|
Series: | International Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971222002089 |
Similar Items
-
Pharmacoeconomic evaluation of isavuconazole, posaconazole, and voriconazole for the treatment of invasive mold diseases in hematological patients: initial therapy prior to pathogen differential diagnosis in China
by: Guangxin Han, et al.
Published: (2023-12-01) -
Isavuconazole for COVID-19-Associated Invasive Mold Infections
by: Nadir Ullah, et al.
Published: (2022-06-01) -
Posaconazole as single or adjunctive antifungal in mucormycosis of the maxilla: systematic review and meta-analysis
by: Pardiwala Arwa, et al.
Published: (2023-01-01) -
Isavuconazole Treatment for Invasive Fungal Infections in Pediatric Patients
by: Philippe Zimmermann, et al.
Published: (2022-03-01) -
Efficacy of combination therapy of amphotericin and posaconazole in treatment of mucormycosis
by: Sridhara S, et al.
Published: (2023-03-01)